Who to call at Nxera Pharma, and when
Fundz watches for the moments Nxera Pharma starts buying, and tells you who to reach.
- An alert the day Nxera Pharma raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Nxera Pharma, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Nxera Pharma. With Fundz connected, it knows.
AbbVie secures exclusive licensing rights to Nxera’s EP4 program for inflammatory bowel disease with a $100 million payment.
Contract Type
partnership
CambridgeBiotechnologyHealth CareDescription
AbbVie is acquiring Nxera Pharma's EP4 receptor agonist program for inflammatory bowel disease for $100 million upfront and potential milestone payments of up to $1.37 billion. This partnership aims to develop and commercialize an oral small molecule, NXE0033744, to better address patient needs in IBD.
Quick answer
AbbVie secures exclusive licensing rights to Nxera’s EP4 program for inflammatory bowel disease with a $100 million payment. (November 4, 2026). Nxera Pharma is based in Cambridge, England, United Kingdom.
- What agreement did Nxera Pharma announce on November 4, 2026?
- AbbVie is acquiring Nxera Pharma's EP4 receptor agonist program for inflammatory bowel disease for $100 million upfront and potential milestone payments of up to $1.37 billion. This partnership aims to develop and commercialize an oral small molecule, NXE0033744, to better address patient needs in IBD.
- What does Nxera Pharma do?
- Nxera Pharma is a technology powered biopharma company, in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally.
- Where is Nxera Pharma based?
- Nxera Pharma is based in Cambridge, England, United Kingdom.
- Which similar companies announced agreements around the same time?
- Wildcat DX (November 4, 2026), JD Technologies Global (November 4, 2026), Physiomics plc (November 4, 2026) and Evommune (November 4, 2026) also announced agreements within 45 days of Nxera Pharma.
Source: Fundz verified event record.
Other recent agreements in Biotechnology and Health Care
Contracts and agreements at companies in the same sectors within 45 days, from Fundz verified event records.
- Wildcat Defense partners with Taqtile to deploy digital tools in shipyards. (November 4, 2026)
- JD Technologies Global and FRIWO North America Form Strategic Partnership to Enhance U.S. Medical Market Access (November 4, 2026)
- Physiomics Wins New Contract for Drug Development Modelling Services (November 4, 2026)
- Evommune Enters Exclusive License Agreement with Hinova Pharmaceuticals (November 4, 2026)
- Teva and Samsung Bioepis Sign Agreement for U.S. Rights to Biosimilars Infliximab and Etanercept. (November 3, 2026)
- Kimia Therapeutics and CStone Pharmaceuticals Collaborate on Clinical Development of KT-721 for Oncology Treatment. (November 5, 2026)
Agreement Insights
What this usually meansNxera Pharma signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.